drugset / Trial / NCT02687178
Canrenone as Add-on in Patients With Essential Hypertension
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy on blood pressure reduction, safety and tolerability of two different dosages of canrenone as add-on therapy in patients already treated with Angiotensin Converting-Enzyme Inhibitors (ACE-I) or Angiotensin II Receptor Blockers (ARBs) and diuretics at the maximum dosage.
Timeline
- Start
- 2010-10
- Primary completion
- 2015-10
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Canrenone | Small molecule | 50 mg | — |
| Comparator | Canrenone | Small molecule | 100 mg | — |